SIGA suspends work on $2.8 billion US smallpox drug contract after Chimerix objects
This article was originally published in Scrip
Just two days after winning the first US contract to develop a smallpox antiviral drug supported through Project BioShield, SIGA Technologies revealed on 15 May that it was forced to suspend further work until a protest from rival Chimerix is resolved, which could take up to about three months.
You may also be interested in...
With new funding in hand, Moderna and its infectious disease venture Valera are going full-speed ahead with a Zika vaccine, taking an mRNA approach, which they said could be a more rapid strategy to try to stop the disease.
Allergan CEO Brent Saunders vows not to engage in price gouging and says his firm will limit cost increases to single-digit percentages, occurring only once per year. But it's unclear whether Saunders will stand as a lone wolf in the industry or if others will make similar pledges.
Hillary Clinton's plan to rein in high prices of older medicines, which includes creating a federal panel that has authority to impose fines, may grab headlines, but some analysts think it's unlikely to get very far in a divided Washington.